Effect of blood group on idiopathic thrombotic thrombocytopenic purpura

Journal of Clinical Apheresis

Volumn 24, Issue 4, 2009, Pages 131-133

  Zuberi, Lara ^a   Yerasuri, Durga ^a   Kuriakose, Philip ^a  

^a HENRY FORD HOSPITAL   (United States)

Author keywords

ADAMTS13; Race; Von Willebrand

Indexed keywords

ARTICLE; BLOOD GROUP A; BLOOD GROUP AB; BLOOD GROUP ABO SYSTEM; BLOOD GROUP B; BLOOD GROUP O; CONTROLLED STUDY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MAJOR CLINICAL STUDY; MORTALITY; POPULATION DISTRIBUTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREND STUDY;

ABO BLOOD-GROUP SYSTEM; ADAM PROTEINS; BLOOD GROUP ANTIGENS; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC; VON WILLEBRAND FACTOR;

EID: 69249100907     PISSN: 07332459     EISSN: 10981101     Source Type: Journal    
DOI: 10.1002/jca.20202     Document Type: Article

References (15)

1. Bowen DJ, Collins PW. An aminoacid polymorphism in Von Willebrand factor correlates with increased susceptibility to proteolysis by ADAMTS13. Blood 2004;103:941-947.
2. Meisenberg BR, Robinson WL, Mosley CA, Duke MS, Rabetoy GM, Kosty MP. Thrombotic thrombocytopenic purpura in human immunodeficiency (HIV)-seropositive males. Am J Hematol 1988;27:212-215.
3. Kolker O, Sviri S, Linton DM, Or R, Nagler A, Shapira MY. Plasmapheresis for thrombotic thrombocytopenic purpura following bone marrow transplantation. Acta Haematol 2001; 105:156-158.
4. Majithia V, Harisdangkul V. Thrombotic thrombocytopenic purpura in systemic lupus erythematosus: a frequent and severe consequence of active disease. Rheumatology 2006;45:1170-1171.
5. Kierdorf H, Maurin N, Heintz B. Cyclosporine for thrombotic thrombocytopenic purpura. Ann Intern Med 1993;118:987-988.
6. Bobbio-Pallavicini E, Gugliotta L, Centurioni R, Porta C, Vianelli N, Billio A, Tacconi F, Ascari E. Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP). Results of a randomized multicenter trial by the Italian Cooperative Group for TTP. Haematologica 1997;82:429-435.
7. Orstavik KH, Magnus P, Reisner H, Berg K, Graham JB, Nance W. Factor VIII and factor IX in a twin population: evidence for a major effect of ABO locus on factor VIII level. Am J Hum Genet 1985;37:89-101.
8. Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A. A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 2008;111:3540-3545.
9. Gill JC, Endres-Brooks J, Bauer PJ, Marks WJ Jr., Montgomery RR. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 1987;69:1691-1695.
10. Davies JA, Collins PW, Hathaway LS, Bowen DJ. Von Willebrand factor: evidence of variable clearance in vivo according to Y/C 1584 phenotype and ABO blood group. J Thromb Haemost 2008;6:97-103.
11. Kostousov V, Fehr J, Bombeli T. Novel, semi-automated, 60-min-assay to determine von Willebrand factor cleaving activity of ADAMTS13. Thromb Res 2006;118:723-731.
12. Furlan M, Robles R, Galbusera M, Remuzzi G, Kyrle PA, Brenner B, Krause M, Scharrer I, Aumann V, Mittler U, Solenthaler M, Lämmle B. von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med 1998;339:1578-1584.
13. Tsai HM, Lian EC. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 1998;339:1585-1594.
14. Mannucci PM, Capoferri C, Canciani MT. Plasma levels of von Willebrand factor regulate ADAMTS-13, its major cleaving protease. Br J Haematol 2004;126:213-218.
15. Chion CK, Doggen CJ, Crawley JT, Lane DA, Rosendaal FR. ADAMTS13 and Von Willebrand factor and the risk of myocardial infarction in men. Blood 2007;109:1998-2000.